References
Key articles
Cheung, Albert Y. et al. Conjunctivitis preferred practice pattern. Ophthalmology. 2024 Feb 12;131(4): 134-204.Full text
Castillo M, Scott NW, Mustafa MZ, et al. Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis. Cochrane Database Syst Rev. 2015 Jun 1;(6):CD009566.Full text Abstract
Chen YY, Liu SH, Nurmatov U, et al. Antibiotics versus placebo for acute bacterial conjunctivitis. Cochrane Database Syst Rev. 2023 Mar 13;3(3):CD001211.Full text Abstract
Reference articles
1. Cheung, Albert Y. et al. Conjunctivitis preferred practice pattern. Ophthalmology. 2024 Feb 12;131(4): 134-204.Full text
2. Shields T, Sloan PD. A comparison of eye problems in primary care and ophthalmology practices. Fam Med. 1991 Sep-Oct;23(7):544-6. Abstract
3. Manners T. Managing eye conditions in general practice. BMJ. 1997 Sep 27;315(7111):816-7. Abstract
4. Royal College of General Practitioners, Royal College of Ophthalmologists. Ophthalmology for general practice trainees. London: Medical Protection Society; 2001.
5. Rietveld RP, ter Riet G, Bindels PJ, et al. Do general practitioners adhere to the guideline on infectious conjunctivitis? Results of the Second Dutch National Survey of General Practice. BMC Fam Pract. 2007 Sep 16;8:54.Full text Abstract
6. Dart JK, Buckley RJ, Monnickendan M, et al. Perennial allergic conjunctivitis: definition, clinical characteristics and prevalence. A comparison with seasonal allergic conjunctivitis. Trans Ophthalmol Soc UK. 1986;105(Pt 5):513-20. Abstract
7. Ono SJ, Abelson MB. Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. J Allergy Clin Immunol. 2005 Jan;115(1):118-22. Abstract
8. Buckley RJ. Allergic eye disease: a clinical challenge. Clin Exp Allergy. 1998 Dec;28 Suppl 6:39-43. Abstract
9. Bielory L. Differential diagnoses of conjunctivitis for clinical allergist-immunologists. Ann Allergy Asthma Immunol. 2007 Feb;98(2):105-14; quiz 114-7, 152. Abstract
10. Choi SH, Bielory L. Late-phase reaction in ocular allergy. Curr Opin Allergy Clin Immunol. 2008 Oct;8(5):438-44. Abstract
11. Meltzer EO, Farrar JR, Sennett C. Findings from an online survey assessing the burden and management of seasonal allergic rhinoconjunctivitis in US patients. J Allergy Clin Immunol Pract. 2017 May-Jun;5(3):779-89.e6.Full text Abstract
12. Bruschi G, Ghiglioni DG, Cozzi L, et al. Vernal keratoconjunctivitis: a systematic review. Clin Rev Allergy Immunol. 2023 Aug;65(2):277-329.Full text Abstract
13. Alemayehu AM, Yibekal BT, Fekadu SA. Prevalence of vernal keratoconjunctivitis and its associated factors among children in Gambella town, southwest Ethiopia, June 2018. PLoS One. 2019;14(4):e0215528.Full text Abstract
14. Johnson D, Liu D, Simel D. Does this patient with acute infectious conjunctivitis have a bacterial infection?: the Rational Clinical Examination Systematic Review. JAMA. 2022 Jun 14;327(22):2231-7. Abstract
15. Choi CJ, Jakobiec FA, Zakka FR, et al. Conjunctival squamous cell neoplasia associated with ocular cicatricial pemphigoid. Ophthalmic Plast Reconstr Surg. 2017 Nov/Dec;33(6):e157-60.Full text Abstract
16. Stenson S, Newman R, Fedukowicz H. Laboratory studies in acute conjunctivitis. Arch Ophthalmology. 1982 Aug;100(8):1275-7. Abstract
17. Weiss A, Brinser J, Nazar-Stewart V. Acute conjunctivitis in childhood. J Pediatr Med. 1993 Jan;122(1):10-4. Abstract
18. Gigliotti F, Williams WT, Hayden FG. Etiology of acute conjunctivitis in children. J Pediatr. 1981 Apr;98(4):531-6. Abstract
19. Singh RB, Liu L, Anchouche S, et al. Ocular redness - I: etiology, pathogenesis, and assessment of conjunctival hyperemia. Ocul Surf. 2021 Jul;21:134-44.Full text Abstract
20. Ullman S, Roussel TJ, Culbertson WW, et al. Neisseria gonorrhoeae keratoconjunctivitis. Ophthalmology. 1987 May;94(5):525-31. Abstract
21. Johnson A. Ocular complications of cat scratch disease. Br J Ophthalmol. 2020 Dec;104(12):1640-6. Abstract
22. Durand ML, Barshak MB, Sobrin L. Eye infections. N Engl J Med. 2023 Dec 21;389(25):2363-75. Abstract
23. Azari AA, Arabi A. Conjunctivitis: a systematic review. J Ophthalmic Vis Res. 2020 Jul-Sep;15(3):372-95.Full text Abstract
24. Sambursky RP, Fram N, Cohen EJ. The prevalence of adenoviral conjunctivitis at the Wills Eye Hospital emergency room. Optometry. 2007 May;78(5):236-9. Abstract
25. Kinchington PR, Turse SE, Kowalski RP, et al. Use of polymerase chain amplification reaction for the detection of adenoviruses in ocular swab specimens. Invest Ophthalmol Vis Sci. 1994 Nov;35(12):4126-34. Abstract
26. Gordon YJ, Gordon RY, Romanowski E, et al. Prolonged recovery of desiccated adenoviral serotypes 5, 8, and 19 from plastic and metal surfaces in vitro. Ophthalmology. 1993 Dec;100(12):1835-9; discussion 1839-40. Abstract
27. Azar MJ, Dhaliwal DK, Bower KS, et al. Possible consequences of shaking hands with your patients with epidemic keratoconjunctivitis. Am J Ophthalmol. 1996 Jun;121(6):711-2. Abstract
28. Paley GL, Lubniewski AJ, Reidy JJ, et al. Toxic keratoconjunctivitis. Eye Contact Lens. 2018 Sep;44(Suppl 1):S8-15. Abstract
29. Ahn H, Ji YW, Jun I, et al. Effects of meibomian gland dysfunction and aqueous deficiency on friction-related disease. Ocul Surf. 2022 Oct;26:295-9. Abstract
30. Lin A, Ahmad S, Amescua G, et al. Blepharitis preferred practice pattern®. Ophthalmology. 2024 Apr;131(4):P50-86.Full text Abstract
31. Amescua G, Ahmad S, Cheung AY, et al. Dry eye syndrome preferred practice pattern®. Ophthalmology. 2024 Apr;131(4):P1-49.Full text Abstract
32. Woo YR, Kim HS. Deciphering childhood rosacea: a comprehensive review. J Clin Med. 2024 Feb 16;13(4):1126.Full text Abstract
33. Gupta S. Giant fornix syndrome. BMJ 2015 Dec 09;351:h6274.Full text
34. Wu D, Daniel BS, Lai AJX, et al. Dupilumab-associated ocular manifestations: A review of clinical presentations and management. Surv Ophthalmol. 2022 Sep-Oct;67(5):1419-42. Abstract
35. Halling AS, Loft N, Silverberg JI, et al. Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis. J Am Acad Dermatol. 2021 Jan;84(1):139-47. Abstract
36. Dupuis P, Prokopich CL, Hynes A, et al. A contemporary look at allergic conjunctivitis. Allergy Asthma Clin Immunol. 2020;16:5.Full text Abstract
37. O'Callaghan RJ. The pathogenesis of Staphylococcus aureus eye infections. Pathogens. 2018 Jan 10;7(1):9.Full text Abstract
38. Chen R, Yang J, Zhang C, et al. Global associations of air pollution and conjunctivitis diseases: a systematic review and meta-analysis. Int J Environ Res Public Health. 2019 Sep 28;16(19):3652.Full text Abstract
39. Bao J, Tian L, Meng Y, et al. Total IgE in tears accurately reflects the severity and predicts the prognosis of seasonal allergic conjunctivitis. Clin Transl Allergy. 2022 Mar;12(3):e12139.Full text Abstract
40. Fitch CP, Rapoza PA, Owens S. Epidemiology and diagnosis of acute conjunctivitis at an inner-city hospital. Ophthalmology. 1989 Aug;96(8):1215-20. Abstract
41. Nche EN, Okwen MM, Solomon A. Prevalence and clinical characteristics of vernal keratoconjunctivitis in sub-Saharan Africa. Curr Opin Allergy Clin Immunol. 2023 Oct 1;23(5):423-9. Abstract
42. Addis H, Jeng BH. Vernal keratoconjunctivitis. Clin Ophthalmol. 2018;12:119-23.Full text Abstract
43. Dart J. Corneal toxicity: the epithelium and stroma in iatrogenic and factitious disease. Eye (Lond). 2003 Nov;17(8):886-92.Full text Abstract
44. Lai NS, Tsai TY, Koo M, Lu MC. Association of rheumatoid arthritis with allergic diseases: a nationwide population-based cohort study. Allergy Asthma Proc. 2015 Sep-Oct;36(5):99-103. Abstract
45. Wollenberg A, Beck LA, de Bruin Weller M, et al. Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials. Br J Dermatol. 2022 Mar;186(3):453-65.Full text Abstract
46. Centers for Disease Control and Prevention. Adult immunization schedule by age (addendum updated June 27, 2024). Nov 2024 [internet publication].Full text
47. Sambursky R, Trattler W, Tauber S, et al. Sensitivity and specificity of the AdenoPlus test for diagnosing adenoviral conjunctivitis. JAMA Ophthalmol. 2013 Jan;131(1):17-22. Abstract
48. American Academy of Ophthalmology. EyeWiki: conjunctivitis. Jun 2024 [internet publication].Full text
49. O'Brien TP, Jeng BH, McDonald M, et al. Acute conjunctivitis: truth and misconceptions. Curr Med Res Opin. 2009 Aug;25(8):1953-61. Abstract
50. Leibowitz HW, Pratt MV, Flagstad IJ, et al. Human conjunctivitis. I. Diagnostic evaluation. Arch Ophthalmol. 1976 Oct;94(10):1747-9. Abstract
51. Cheung D, Bremner J, Chan JT. Epidemic kerato-conjunctivitis: do outbreaks have to be epidemic? Eye (Lond). 2003 Apr;17(3):356-63. Abstract
52. Sambursky R, Tauber S, Schirra F, et al. The RPS adeno detector for diagnosing adenoviral conjunctivitis. Ophthalmology. 2006 Oct;113(10):1758-64. Abstract
53. Chien L, Llaues-Rodas R. Application of immunofluorescent staining technique to the study of pathogenesis and rapid diagnosis of viral infections. Am J Clin Pathol. 1972 Jun;57(6):829-34. Abstract
54. Van Rij G, Klepper L, Perkamp E, et al. Immune electron microscopy and a cultural test in the diagnosis of adenovirus ocular infection. Br J Ophthalmol. 1982 May;66(5):317-9. Abstract
55. Wadell G, Allard A, Hierholzer JC. Adenoviruses. In: Murray PR, Baron EJ, Pfaller MA, et al., eds. Manual of clinical microbiology. 7th ed. Washington, DC: American Society for Microbiology; 1999.
56. American Academy of Ophthalmology. Cornea/external disease summary benchmarks - 2023. Dec 2023 [internet publication].Full text
57. American Academy of Ophthalmology. Referral of persons with possible eye diseases or injury. Apr 2014 [internet publication].Full text
58. Adleberg JM, Wittwer C. Use of the polymerase chain reaction in the diagnosis of ocular disease. Curr Opin Ophthalmol. 1995 Jun;6(3):80-5. Abstract
59. Elnifro EM, Cooper RJ, Klapper PE, et al. Diagnosis of viral and chlamydial keratoconjunctivitis: which laboratory test? Br J Ophthalmol. 1999 May;83(5):622-7. Abstract
60. Elnifro EM, Cooper RJ, Klapper PE, et al. Multiplex polymerase chain reaction for diagnosis of viral and chlamydial keratoconjunctivitis. Invest Ophthalmol Vis Sci. 2000 Jun;41(7):1818-22. Abstract
61. American Academy of Ophthalmology. Pediatric eye evaluations preferred practice pattern. Dec 2022 [internet publication].Full text Abstract
62. American Academy of Ophthalmology. Comprehensive adult medical eye evaluation preferred practice pattern®. Nov 2020 [internet publication].Full text
63. American Academy of Ophthalmology. Frequency of ocular examinations. Mar 2015 [internet publication].Full text
64. Castillo M, Scott NW, Mustafa MZ, et al. Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis. Cochrane Database Syst Rev. 2015 Jun 1;(6):CD009566.Full text Abstract
65. Bilkhu PS, Wolffsohn JS, Naroo SA, et al. Effectiveness of nonpharmacologic treatments for acute seasonal allergic conjunctivitis. Ophthalmology. 2014 Jan;121(1):72-8.Full text Abstract
66. Bonini S, Gramiccioni C, Bonini M, et al. Practical approach to diagnosis and treatment of ocular allergy: a 1-year systematic review. Curr Opin Allergy Clin Immunol. 2007 Oct;7(5):446-9. Abstract
67. Bielory L, Katelaris CH, Lightman S, et al. Treating the ocular component of allergic rhinoconjunctivitis and related eye disorders. MedGenMed. 2007 Aug 15;9(3):35.Full text Abstract
68. Abelson MB, Gomes PJ. Olopatadine 0.2% ophthalmic solution: the first ophthalmic antiallergy agent with once-daily dosing. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):453-61. Abstract
69. Gonzalez-Estrada A, Reddy K, Dimov V, et al. Olopatadine hydrochloride ophthalmic solution for the treatment of allergic conjunctivitis. Expert Opin Pharmacother. 2017 Aug;18(11):1137-43. Abstract
70. Kam KW, Chen LJ, Wat N, et al. Topical olopatadine in the treatment of allergic conjunctivitis: a systematic review and meta-analysis. Ocul Immunol Inflamm. 2017 Oct;25(5):663-77. Abstract
71. Dou XY, Zhang W. Topical ketotifen treatment for allergic conjunctivitis: a systematic review and Meta-analysis. Int J Ophthalmol. 2023;16(2):286-92.Full text Abstract
72. Olopatadine for the treatment of allergic conjunctivitis: a review of the clinical efficacy, safety, and cost-effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2016.Full text Abstract
73. Schechter BA. Ketorolac tromethamine 0.4% as a treatment for allergic conjuctivitis. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):507-11. Abstract
74. Gong L, Sun X, Qu J, et al. Loteprednol etabonate suspension 0.2% administered QID compared with olopatadine solution 0.1% administered BID in the treatment of seasonal allergic conjunctivitis: a multicenter, randomized, investigator-masked, parallel group study in Chinese patients. Clin Ther. 2012 Jun;34(6):1259-72. Abstract
75. Oner V, Türkcü FM, Taş M, et al. Topical loteprednol etabonate 0.5 % for treatment of vernal keratoconjunctivitis: efficacy and safety. Jpn J Ophthalmol. 2012 Jul;56(4):312-8. Abstract
76. Liu RF, Wu XX, Wang X, et al. Efficacy of olopatadine hydrochloride 0.1%, emedastine difumarate 0.05%, and loteprednol etabonate 0.5% for Chinese children with seasonal allergic conjunctivitis: a randomized vehicle-controlled study. Int Forum Allergy Rhinol. 2017 Apr;7(4):393-8.Full text Abstract
77. Wartna JB, Bohnen AM, Elshout G, et al. Symptomatic treatment of pollen-related allergic rhinoconjunctivitis in children: randomized controlled trial. Allergy. 2017 Apr;72(4):636-44. Abstract
78. Mantelli F, Santos MS, Petitti T, et al. Systematic review and meta-analysis of randomised clinical trials on topical treatments for vernal keratoconjunctivitis. Br J Ophthalmol. 2007 Dec;91(12):1656-61.Full text Abstract
79. Swamy BN, Chilov M, McClellan K, et al. Topical non-steroidal anti-inflammatory drugs in allergic conjunctivitis: meta-analysis of randomized trial data. Ophthalmic Epidemiol. 2007 Sep-Oct;14(5):311-9. Abstract
80. Takamura E, Uchio E, Ebihara N, et al; Japanese Society of Allergology. Japanese guidelines for allergic conjunctival diseases 2017. Allergol Int. 2017 Apr;66(2):220-9.Full text Abstract
81. Berger WE, Granet DB, Kabat AG. Diagnosis and management of allergic conjunctivitis in pediatric patients. Allergy Asthma Proc. 2017 Jan 1;38(1):16-27. Abstract
82. Chen YY, Liu SH, Nurmatov U, et al. Antibiotics versus placebo for acute bacterial conjunctivitis. Cochrane Database Syst Rev. 2023 Mar 13;3(3):CD001211.Full text Abstract
83. Rose P. Management strategies for acute infective conjunctivitis in primary care: a systematic review. Expert Opin Pharmacother. 2007 Aug;8(12):1903-21. Abstract
84. Sheikh A, Hurwitz B. Topical antibiotics for acute bacterial conjunctivitis: a systematic review. Br J Gen Pract. 2001 Jun;51(467):473-7. Abstract
85. Honkila M, Koskela U, Kontiokari T, et al. Effect of topical antibiotics on duration of acute infective conjunctivitis in children: a randomized clinical trial and a systematic review and meta-analysis. JAMA Netw Open. 2022 Oct 3;5(10):e2234459.Full text Abstract
86. Denis F, Chaumeil C, Goldschmidt P, et al. Microbiological efficacy of 3-day treatment with azithromycin 1.5% eye-drops for purulent bacterial conjunctivitis. Eur J Ophthalmol. 2008 Nov-Dec;18(6):858-68. Abstract
87. Abelson MB, Heller W, Shapiro AM, et al; AzaSite Clinical Study Group. Clinical cure of bacterial conjunctivitis with azithromycin 1%: vehicle-controlled, double-masked clinical trial. Am J Ophthalmol. 2008 Jun;145(6):959-65. Abstract
88. Protzko E, Bowman L, Abelson M, et al; AzaSite Clinical Study Group. Phase 3 safety comparisons for 1.0% azithromycin in polymeric mucoadhesive eye drops versus 0.3% tobramycin eye drops for bacterial conjunctivitis. Invest Ophthalmol Vis Sci. 2007 Aug;48(8):3425-9.Full text Abstract
89. Mah F. Bacterial conjunctivitis in pediatrics and primary care. Pediatr Clin North Am. 2006 May;53 Suppl 1:7-10; quiz 11, 13-5. Abstract
90. Alfonso E, Crider J. Ophthalmic infections and their anti-infective challenges. Surv Ophthalmol. 2005 Nov;50 Suppl 1:S1-6. Abstract
91. Silverstein BE, Morris TW, Gearinger LS, et al. Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections. Clin Ophthalmol. 2012;6:1987-96.Full text Abstract
92. Karpecki P, Depaolis M, Hunter JA, et al. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: a multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study. Clin Ther. 2009 Mar;31(3):514-26. Abstract
93. McDonald MB, Protzko EE, Brunner LS, et al. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis. Ophthalmology. 2009 Sep;116(9):1615-23.e1. Abstract
94. Tepedino ME, Heller WH, Usner DW, et al. Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. Curr Med Res Opin. 2009 May;25(5):1159-69. Abstract
95. Sanfilippo CM, Allaire CM, DeCory HH. Besifloxacin ophthalmic suspension 0.6% compared with gatifloxacin ophthalmic solution 0.3% for the treatment of bacterial conjunctivitis in neonates. Drugs R D. 2017 Mar;17(1):167-75.Full text Abstract
96. O'Brien TP. Besifloxacin ophthalmic suspension, 0.6%: a novel topical fluoroquinolone for bacterial conjunctivitis. Adv Ther. 2012 Jun;29(6):473-90. Abstract
97. Haimovici R, Roussel TJ. Treatment of gonococcal conjunctivitis with single-dose intramuscular ceftriaxone. Am J Ophthalmol. 1989 May 15;107(5):511-4. Abstract
98. Kaufman HE. Ganciclovir: a promising topical antiviral gel for herpetic keratitis. Expert Rev Ophthal. 2009;4(4):367-75.Full text
99. Colin J. Ganciclovir ophthalmic gel, 0.15%: a valuable tool for treating ocular herpes. Clin Ophthalmol. 2007 Dec;1(4):441-53.Full text Abstract
100. Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management of herpes zoster. Clin Infect Dis. 2007 Jan 1;44 Suppl 1:S1-26.Full text Abstract
101. Recommendations for the prevention of neonatal ophthalmia. Paediatr Child Health. 2002 Sep;7(7):480-3.Full text Abstract
102. Matejcek A, Goldman RD. Treatment and prevention of ophthalmia neonatorum. Can Fam Physician. 2013 Nov;59(11):1187-90.Full text Abstract
103. Mahvan TD, Buckley WA, Hornecker JR. Alcaftadine for the prevention of itching associated with allergic conjunctivitis. Ann Pharmacother. 2012 Jul-Aug;46(7-8):1025-32. Abstract
104. Marini MC, Berra ML, Girado F, et al. Efficacy and toxicity evaluation of bepotastine besilate 1.5% preservative-free eye drops vs olopatadine hydrochloride 0.2% bak-preserved eye drops in patients with allergic conjunctivitis. Clin Ophthalmol. 2023;17:3477-89.Full text Abstract
105. D'Cruz OJ, Uckun FM. Stampidine: a selective oculo-genital microbicide. J Antimicrob Chemother. 2005 Jul;56(1):10-9. Abstract
106. Gordon YJ, Romanowski EG, McDermott AM. A review of antimicrobial peptides and their therapeutic potential as anti-infective drugs. Curr Eye Res. 2005 Jul;30(7):505-15. Abstract
107. Monnerat N, Bossart W, Thiel MA. Povidone-iodine for treatment of adenoviral conjunctivitis: an in vitro study [in German]. Klin Monbl Augenheilkd. 2006 May;223(5):349-52. Abstract
108. Isenberg SJ, Apt L, Valenton M, et al. A controlled trial of povidone-iodine to treat infectious conjunctivitis in children. Am J Ophthalmol. 2002 Nov;134(5):681-8. Abstract
109. Yazar H, Yarbag A, Balci M, et al. The effects of povidone iodine (pH 4.2) on patients with adenoviral conjunctivitis. J Pak Med Assoc. 2016 Aug;66(8):968-70. Abstract
110. Pelletier JS, Stewart K, Trattler W, et al. A combination povidone-iodine 0.4%/dexamethasone 0.1% ophthalmic suspension in the treatment of adenoviral conjunctivitis. Adv Ther. 2009 Aug;26(8):776-83. Abstract
111. Epstein SP, Pashinsky YY, Gershon D, et al. Efficacy of topical cobalt chelate CTC-96 against adenovirus in a cell culture model and against adenovirus keratoconjunctivitis in a rabbit model. BMC Ophthalmol. 2006 Jun 5;6:22.Full text Abstract
112. Zanjani H, Aminifard MN, Ghafourian A, et al. Comparative evaluation of tacrolimus versus interferon alpha-2b eye drops in the treatment of vernal keratoconjunctivitis: a randomized, double-masked study. Cornea. 2017 Jun;36(6):675-78. Abstract
113. Zhao M, He F, Yang Y, et al. Therapeutic efficacy of tacrolimus in vernal keratoconjunctivitis: a meta-analysis of randomised controlled trials. Eur J Hosp Pharm. 2020 Nov 3 [Epub ahead of print].Full text Abstract
114. Morrow GL, Abbott RL. Conjunctivitis. Am Fam Physician. 1998 Feb 15;57(4):735-46. Abstract
115. Butt AL, Chodosh J. Adenoviral keratoconjunctivitis in a tertiary care eye clinic. Cornea. 2006 Feb;25(2):199-202. Abstract
116. Colón LE. Keratoconjunctivitis due to adenovirus type 8: report on a large outbreak. Ann Ophthalmol. 1991 Feb;23(2):63-5. Abstract
117. Ankers HE, Klapper PE, Cleator GM, et al. The role of a rapid diagnostic test (adenovirus immune dot blot) in the control of an outbreak of adenovirus type-8 keratoconjunctivitis. Eye. 1993;7(Pt 3 Suppl):15-7. Abstract
118. Jackson WB, Davis PL, Groh V, et al. Adenovirus type 19 keratoconjunctivitis in Canada. Can J Ophthalmol. 1975 Jul;10(3):326-33. Abstract
119. Richmond S, Burman R, Crosdale E, et al. A large outbreak of keratoconjunctivitis due to adenovirus type 8. J Hyg (Lond). 1984 Oct;93(2):285-91. Abstract
120. Hyde KJ, Berger ST. Epidemic keratoconjunctivitis and lacrimal excretory system obstruction. Ophthalm. 1988 Oct;95(10):1447-9. Abstract
121. Hammer LH, Perry HD, Donnenfeld ED, et al. Symblepharon formation in epidemic keratoconjunctivitis. Cornea. 1990 Oct;9(4):338-40. Abstract
Use of this content is subject to our disclaimer